EDITORIAL

Natriuretic peptide receptors and the heart

L King, M R Wilkins

Section on Clinical Pharmacology, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, UK

Correspondence to:
Correspondence to:
Professor Martin R Wilkins, Section on Clinical Pharmacology, Faculty of Medicine, Imperial College, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK;
m.wilkins@ic.ac.uk

---

The synthesis of ANP and BNP by the heart has emerged as a sensor of cardiac strain, with increased synthesis the hallmark of myocyte hypertrophy in cell culture, and raised plasma concentrations a biomarker of ventricle dysfunction in vivo.

---

Keywords: atrial natriuretic peptide; B type natriuretic peptide; natriuretic peptide receptors

Abbreviations: ACE, angiotensin converting enzyme; ANP, atrial natriuretic peptide; BNP, B type natriuretic peptide; NEP, neutral endopeptidase; NPR, natriuretic peptide receptors

It is 20 years since de Bold reported that homogenates of normal atria stimulated a natriuresis and diuresis when administered intravenously to rats.¹ This observation led to the isolation of atrial natriuretic peptide (ANP) from cardiac tissue. Subsequently other peptides with a similar ring structure and biological properties have been recognised, named in alphabetical order—BNP, CNP, and DNP—and termed the natriuretic peptide family.

Initial studies of the biology of natriuretic peptides focused on their endocrine role—measuring circulating levels in response to different stimuli and looking at the effects of administering exogenous peptide to isolated tissues and whole animals. Most attention has been given to ANP and BNP. Both are synthesised by cardiac myocytes and their production is increased by factors that increase cardiac work—pressure and volume overload. Indeed, the cardiac synthesis of ANP and BNP has emerged as a sensor of cardiac strain, with increased synthesis the hallmark of myocyte . . . [Full text of this article]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Gruenig, E., Michelakis, E., Vachiery, J.-L., Vizza, C. D., Meyer, F. J., Doelberg, M., Bach, D., Dingemanse, J., Galie, N. (2009). Acute Hemodynamic Effects of Single-Dose Sildenafil When Added to Established Bosentan Therapy in Patients With Pulmonary Arterial Hypertension: Results of the COMPASS-1 Study. J Clin Pharmacol 49: 1343-1352 [Abstract] [Full Text]  
• Haworth, S. G. (2007). The cell and molecular biology of right ventricular dysfunction in pulmonary hypertension. Eur Heart J Suppl 9: H10-H16 [Abstract] [Full Text]  
• Blyth, K. G., Groenning, B. A., Mark, P. B., Martin, T. N., Foster, J. E., Steedman, T., Morton, J. J., Dargie, H. J., Peacock, A. J. (2007). NT-proBNP can be used to detect right ventricular systolic dysfunction in pulmonary hypertension. Eur Respir J 29: 737-744 [Abstract] [Full Text]  
• Yap, L. B., Mukerjee, D., Timms, P. M., Ashrafian, H., Coghlan, J. G. (2004). Natriuretic Peptides, Respiratory Disease, and the Right Heart. Chest 126: 1330-1336 [Abstract] [Full Text]